Shots:

• The EMA’s CHMP has adopted a positive opinion for Libtayo as monothx. in adult patients with recurrent or metastatic cervical cancer. The EC’s decision is expected in the coming months
• The opinion was based on the P-III (EMPOWER-Cervical 1) trial evaluating Libtayo (350mg, q3w) as monothx. vs CT in 608 patients. The trial met its 1EPs of OS with a 31% reduction in risk of death in the total population & 27% in the SCC population, no new Libtayo safety signals were observed, AEs (10%). The results were published in the NEJM
• Libtayo is a fully human mAb targeting immune checkpoint receptor PD-1 on T cells developed using Regeneron's VelocImmune technology. The therapy was approved in the EU & other countries for BCC, advanced CSCC & NSCLC

Ref:  Regeneron | Image:  Regeneron